Clinical Trial Detail

NCT ID NCT03026062
Title Durvalumab and Tremelimumab in Combo Versus Sequential
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

peritoneum cancer

fallopian tube cancer

ovarian cancer

Therapies

Tremelimumab

Durvalumab + Tremelimumab

Durvalumab

Age Groups: senior adult

No variant requirements are available.